RT-ddPCR assay developed to quantify regions of SARS-CoV-2 RNA
Scientists have created a RT-ddPCR assay to analyse both the non-coding and coding RNA regions of SARS-CoV-2.
List view / Grid view
Scientists have created a RT-ddPCR assay to analyse both the non-coding and coding RNA regions of SARS-CoV-2.
Learn about a practical, high-throughput method for validating the target-specificity of antibodies for the application of western blot.
A modified luciferase enzyme has been developed as an immunosensor to be fused with a Q-body and used in immunoassays.
28 May 2021 | By Eurofins DiscoverX* and Tecan
In this on-demand webinar, we discuss how Eurofins DiscoverX’s off-the-shelf, MOA-based functional, cellular assays address these challenges, enabling drug discovery programmes up to late-stage development and market release.
Researchers have discovered that blocking TRPC5 activity treated chronic pain in mouse models of various conditions.
A wide range of tools to support your immuno-oncology research and help redefine and develop tailored, life-changing immunotherapies to fight cancer.
Chimeric antigen receptor (CAR) T and natural killer (NK) therapies may become the future of cancer treatment. Dr Jim Ross explains how bioelectronic assays are a non-invasive, label-free approach built for real-time, dynamic assessment of cell therapy potency.
Researchers have successfully created an unbiased, high-throughput microtitration assay for the quantification of Ebola virus in cell lines.
A synthetic antiviral named R327 has shown promise in initial tests against SARS-CoV-2 and is now advancing to the next stage of in vitro studies.
A new assay has been developed to screen for small molecule inhibitors of the Rh5 protein, which is essential for malaria parasite survival.
Researchers from the University of Minnesota have developed a 3D spherical microfluidic device. Here, Dr Ruitao Su explains how the new device can be used in drug discovery and development.
Microfluidic screening technologies have been used to discover a promising antibody candidate against SARS-CoV-2 and the South African variant.
A critical stage of the SARS-CoV-2 replication process, known as frameshifting, could be targeted by new drugs, researchers say.
Sino Biological has developed 1,000+ cytokines and receptors, including growth factors, cytokines, chemokines, interferons, interleukins, etc.
The global cell-based assays market is expected to grow due to increasing investments into cell-based research and a rise in chronic diseases.